Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.
Nomura M, Ohashi T, Nishikawa K, Nishitsuji H, Kurihara K, Hasegawa A, Furuta RA, Fujisawa J, Tanaka Y, Hanabuchi S, Harashima N, Masuda T, Kannagi M. Nomura M, et al. Among authors: nishikawa k. J Virol. 2004 Apr;78(8):3827-36. doi: 10.1128/jvi.78.8.3827-3836.2004. J Virol. 2004. PMID: 15047798 Free PMC article.
Presumptive role of 129 strain-derived Sle16 locus in rheumatoid arthritis in a new mouse model with Fcγ receptor type IIb-deficient C57BL/6 genetic background.
Sato-Hayashizaki A, Ohtsuji M, Lin Q, Hou R, Ohtsuji N, Nishikawa K, Tsurui H, Sudo K, Ono M, Izui S, Shirai T, Takai T, Nishimura H, Hirose S. Sato-Hayashizaki A, et al. Among authors: nishikawa k. Arthritis Rheum. 2011 Oct;63(10):2930-8. doi: 10.1002/art.30485. Arthritis Rheum. 2011. PMID: 21953083 Free article.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Sugimoto N, Kawada J, Oka Y, Ueda S, Murakami K, Nishikawa K, Kurokawa Y, Fujitani K, Kawakami H, Endo S, Sakai D, Shimokawa T, Satoh T. Sugimoto N, et al. Among authors: nishikawa k. Anticancer Res. 2025 Jan;45(1):307-313. doi: 10.21873/anticanres.17418. Anticancer Res. 2025. PMID: 39740851 Clinical Trial.
2,282 results